title: Chronic natural killer cell lymphocytosis: a descriptive clinical study.
abstract: We review the clinical manifestations and long-term outlook of patients with chronic natural killer (NK) cell lymphocytosis. After reviewing more than 1,500 peripheral blood lymphoid flow cytometry reports and molecular genetics data from patients with suspected large granular lymphocyte (LGL) proliferation, we identified 10 patients (median age at diagnosis, 60 years; range, 35 to 76 years; male:female ratio, 3:2) with persistent (greater than 6 months) increase in phenotypically determined NK cells (CD3-CD16+). Southern blot analysis performed on 9 patients showed no clonal T-cell receptor gene rearrangements. Disease duration was measured from time of initial recognition of LGL or NK cell excess (greater than 40% of the lymphocyte fraction). Clinical data from these 10 patients were compared with those from 68 patients with T-cell LGL (T-LGL) leukemia. Currently, all patients are alive (median disease duration, 5 years; range, 0.8 to 8 years). Associated disease manifestations included pure red blood cell aplasia, recurrent neutropenia, recurrent neutropenic sepsis, and vasculitic syndromes, all of which were responsive to immunosuppressive therapy. No patient had palpable lymphadenopathy or splenomegaly. Compared with the patients with T-LGL leukemia, patients with chronic NK cell leukemia has similar lymphocyte counts, associated conditions, treatment responses, and survival but had less neutropenia and anemia.
authors.affiliation: Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905.
authors.forename: A
authors.initials: A
authors.lastname: Tefferi
authors.forename: C Y
authors.initials: CY
authors.lastname: Li
authors.forename: T E
authors.initials: TE
authors.lastname: Witzig
authors.forename: M V
authors.initials: MV
authors.lastname: Dhodapkar
authors.forename: S H
authors.initials: SH
authors.lastname: Okuno
authors.forename: R L
authors.initials: RL
authors.lastname: Phyliky
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D015139:Blotting, Southern; D017252:CD3 Complex / Q000032:analysis; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D015329:Gene Rearrangement, T-Lymphocyte; D006801:Humans; D016130:Immunophenotyping; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000276:immunology / Q000473:pathology; D015458:Leukemia, T-Cell; D008218:Lymphocytosis / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000150:complications; D017452:Receptors, IgG / Q000032:analysis; D012010:Red-Cell Aplasia, Pure / Q000150:complications; D014657:Vasculitis / Q000150:complications
chemical_list: D000305:Adrenal Cortex Hormones; D017252:CD3 Complex; D007166:Immunosuppressive Agents; D017452:Receptors, IgG; D003520:Cyclophosphamide